Abstract Library

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy

Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Aalbersberg E, Versleijen M, Tesselaar M, Walraven I,

Keywords: PRRT, RECIST, 68Ga-DOTATATE PET/CT, response,

#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors

Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Peiró I, Vercher-Conejero J, Suils-Ramón J, Hernández L, Teulé A,

Keywords: 68Ga-DOTATOC PET/CT, metastatic neuroendocrine tumors,

#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan

Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mapelli P, Ironi G, Partelli S, Andreasi V, Muffatti F,

Keywords: 68Ga-DOTATOC, PET/MRI, NET, staging, restaging,